Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Regeneron Rises After Eye Drug Sales Beat Analyst Estimate

Regeneron Pharmaceuticals Inc. increased 14 percent after net sales for the company’s Eylea drug used to treat a blindness-causing eye disorder were more than four times what analysts estimated.

Regeneron rose to $74.44 at the close in New York, the company’s biggest one-day climb since April 27. The drug, used to treat wet age-related macular degeneration, produced $24 million to $25 million in sales from Nov. 21 to Dec. 31, the Tarrytown, New York-based company said yesterday. Regeneron said that 2012 sales from the medicine would reach $140 million to $160 million.

Eylea competes with Roche Holding AG’s Lucentis, the Basel, Switzerland-based drugmaker’s fifth biggest-selling medicine at 1.46 billion Swiss francs ($1.4 billion) in 2010. More than 10,000 Eylea doses have been distributed to doctors, Len Schleifer, Regeneron’s chief executive officer, said in an interview. The company said that included pent-up demand from difficult-to-treat patients, Christopher J. Raymond, an analyst at Robert W. Baird in Chicago, wrote in a note to investors.

“Backing out stocking, it’s still a big number,” Raymond wrote. Raymond raised his rating on Regeneron to “outperform” and increased his target price for the shares to $81.

Baird had estimated $2 million in Eylea sales, according to the note. Phil Nadeau, an analyst with Cowen & Co., had estimated the drug would generate $5 million in the fourth quarter.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.